Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interchangeability of TRS003 and Bevacizumab in Metastatic Colorectal Cancer
NCT05378867Phase 3Unknown
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of RPH-001 in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Zhejiang Teruisi Pharmaceutical Inc. Primary endpoint: Area under the curve over the dosing interval at Cycle 14. Status: unknown.
02
Drugs
RPH-001
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05378867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378867.